$heff's $tation of $tocks & $olid DD

[$$$eeker]

Rockwell Medical to Discuss Top-Line Results From Final SFP Phase 3 Efficacy Study CRUISE-2
Conference Call Wednesday, September 4, 2013 at 8:30am EDT
WIXOM, MI--(Marketwired - Sep 3, 2013) - Rockwell Medical (NASDAQ: RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis, will host a conference call tomorrow, Wednesday, September 4th at 8:30am EDT to review top-line results from their Phase 3 (CRUISE-2) efficacy study of SFP, the Company's late-stage investigational iron-delivery drug for the treatment of iron deficiency in chronic kidney disease patients receiving hemodialysis. Rockwell will announce the top-line results tomorrow morning prior to the call.
On the call from Rockwell will be Rob Chioini, Founder, Chairman and Chief Executive Officer, Dr. Raymond Pratt, Chief Medical Officer, and Dr. Ajay Gupta, Chief Scientific Officer.
To participate in the conference call, please call 1-877-383-7438 (U.S.), 1-678-894-3975 (outside the U.S.), call-in ID: 49150189. The call will be webcast simultaneously at http://ir.rockwellmed.com/events.cfm and will be available for replay at this link for 14 days.
http://yhoo.it/13aOEf3